ctDNA Testing Showed High Prognostic Accuracy In Detecting Recurrence Of MCC, Study Finds

OncLive (8/5, Seymour) reports, “Use of circulating tumor DNA (ctDNA) testing demonstrated high baseline sensitivity and specificity prior to treatment, and the presence of ctDNA showed an association with risk of recurrence post-treatment in patients with Merkel cell carcinoma (MCC), according to findings from a study.” OncLive adds, “In the discovery cohort, baseline sensitivity for detecting ctDNA in patients with clinically evident disease was 95% (95% CI, 87%-99%); its specificity for detecting ctDNA negativity in patients without clinically evident disease was 90% (95% CI, 82%-95%).” Meanwhile, “in the validation cohort, baseline sensitivity and specificity for detecting ctDNA in patients with clinically evident disease was 94% (95% CI, 85%-98%) and 86% (95% CI, 77%-93%), respectively.” The research was published in the Journal of Clinical Oncology.